Patient reported outcomes following MR-guided radiotherapy for prostate cancer: a systematic review and meta-analysis

J M Westerhoff, T A Lalmahomed, L Meijers, L Henke, F R Teunissen, A M E Bruynzeel, F Alongi, W A Hall, A U Kishan, M P W Intven, H M Verkooijen, J R N van der Voort van Zyp, L A Daamen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

PURPOSE: This systematic review provides an overview of literature on the impact of MR-guided radiotherapy (MRgRT) on patient reported outcomes (PROs) in patients with prostate cancer (PC).

METHODS: A systematic search was performed in October 2023 in PubMed, EMBASE and Cochrane Library. The PICOS framework (i.e., patient, intervention, comparison, outcome, study design) was used to determine eligibility criteria. Included were studies assessing PROs following MRgRT for PC with sample size >10. Methodological quality was assessed using the ROBINS-I and RoB 2. Relevant mean differences (MD) compared to pre-RT were interpreted using minimal important differences (MID). Meta-analyses were performed using random-effects models. Between-study heterogeneity was assessed using the I 2-statistic.

RESULTS: Eleven observational studies and one randomized controlled trial (n=897) were included. Nine studies included patients with primary PC with MRgRT as first-line treatment (n=813) and three with MRgRT as second-line treatment (n=84). Substantial risk of bias was found in five studies. EORTC QLQ-C30 and EORTC QLQ-PR25 scores were pooled from three studies, and EPIC-26 scores from four studies. Relevant MDs for the urinary domain were found with the EPIC-26 (MD-10.0 [95%CI -12.0 - -8.1]; I 20%) and the EORTC QLQ-PR25 (MD8.6 [95%CI -4.7-22.0]; I 297%), both at end-RT to one month follow-up. Relevant MDs for the bowel domain were found with the EPIC-26 (MD-4.7 [95%CI -9.2 - -0.2]; I 282%), at end-RT or one month follow-up, but not with the EORTC QLQ-PR25. For both domains, no relevant MDs were found after three months of follow-up. No relevant MDs were found in the general QoL domains of the EORTC QLQ-C30.

CONCLUSION: MRgRT for PC results in a temporarily worsening of patient-reported urinary and bowel symptoms during the first month after treatment compared to pre-RT, resolving at 3 months. No clinically relevant changes were found for general QoL domains. These results provide important information for patient counseling and can serve as a benchmark for future studies.

Original languageEnglish
Pages (from-to)38-48
JournalInternational journal of radiation oncology, biology, physics
Volume120
Issue number1
Early online date3 Jun 2024
DOIs
Publication statusPublished - 1 Sept 2024

Fingerprint

Dive into the research topics of 'Patient reported outcomes following MR-guided radiotherapy for prostate cancer: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this